Successful treatment with ustekinumab in CARD14‐associated papulosquamous eruption in a Brazilian child

Kiszewski, Ana Elisa; Almeida, Hiram Laranjeira de

doi:10.1111/dth.15939

Cited by 7 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The upregulation of CARD14 lead to excessive expression of NF-kBresponsive genes and initiate the recruitment of the inflammatory cells, including dendritic cells and T cells producing IL-23 and IL-17/IL-22 respectively (47). In line with this, ustekinumab, an inhibitor that targets both IL-12 and IL-23 cytokines, proved to be a successful treatment in an increasing numbers of patients with CARD14 GOF mutations (45,(48)(49)(50)(51). Since the role of CARD14 in both AD and psoriatic diseases, targeted therapies in these patients need to be considered with caution.…”

Section: Card14mentioning

confidence: 97%

Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement

et al. 2023

View full text Add to dashboard Cite

Inborn errors of immunity associated with atopy (IEIs-A) are a group of inherited monogenic disorders that occur with immune dysregulation and frequent skin involvement. Several pathways are involved in the pathogenesis of these conditions, including immune system defects, alterations of skin barrier and metabolism perturbations. Current technological improvements and the higher accessibility to genetic testing, recently allowed the identification of novel molecular pathways involved in IEIs-A, also informing on potential tailored therapeutic strategies. Compared to other systemic therapy for skin diseases, biologics have the less toxic and the best tolerated profile in the setting of immune dysregulation. Here, we review IEIs-A with skin involvement focusing on the tailored therapeutic approach according to their pathogenetic mechanism.

show abstract